Clinical efficacy of decitabine combined with half dose CAG regimen in treatment of patients with relapsed/refractory acute myeloid leukemia / 白血病·淋巴瘤

ABSTRACT

Objective To observe the clinical efficacy of decitabine combined with half dose CAG regimen in patients with relapsed/refractory acute myeloid leukemia (AML).Methods Clinical data of 8 patients with relapsed/refractory AML who took the therapeutic regimen with decitabine combined with half dose CAG regimen in the Third People's Hospital of Datong from January 2015 to January 2017 were collected.The clinical efficacy and adverse effects were observed.Results After one course treatment by decitabine combined with half dose CAG regimen,3 patients achieved complete remission,and 2 patients achieved partial remission.The major adverse reactions were myelosuppression and infection,8 patients appeared grade Ⅲ-Ⅳ myelosuppression,5 patients appeared infection,2 patients appeared grade Ⅰ abnormality of liver and no treatment-related death occurred.Conclusion Decitabine combined with half dose CAG regimen is effective for relapsed/refractory AML,and this regimen is worthy of further study.